Natte krant schreef op 27 januari 2016 15:01:
seekingalpha.com/article/3837906-euro...MDxHealth (OTC:MXDHF) - The Belgian molecular diagnostics specialist just reported its largest sales volume increase in the last years with projected annual revenues of $16-20 million. While it is mostly known by U.S. investors for lending its technology platform to Exact Sciences' (NASDAQ:EXAS) Cologuard, the biotech is clearly making a name for itself in the U.S. diagnostics landscape independently from the fortunes of its American licensee. With its wholly-owned prostate cancer tests, ConfirmMDx and SelectMDx (which make up to 90% of the company's revenues), MDxHealth sold over 15.000 tests worldwide in 2015 and closed another string of significant insurance coverage deals - this has yet to translate into sizeable profits, as the company's net loss is improving quite slowly due to heavy operational expenses, but the path to sustainability is now quite clear.